Protagonist Therapeutics, Inc. (NASDAQ:PTGX) Holdings Lifted by JPMorgan Chase & Co.

JPMorgan Chase & Co. lifted its holdings in shares of Protagonist Therapeutics, Inc. (NASDAQ:PTGX - Free Report) by 12.9% during the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 576,977 shares of the company's stock after acquiring an additional 65,792 shares during the quarter. JPMorgan Chase & Co. owned 0.97% of Protagonist Therapeutics worth $22,271,000 as of its most recent filing with the SEC.

A number of other hedge funds and other institutional investors have also modified their holdings of the business. Maryland State Retirement & Pension System grew its stake in Protagonist Therapeutics by 1.4% during the 4th quarter. Maryland State Retirement & Pension System now owns 20,170 shares of the company's stock valued at $779,000 after purchasing an additional 278 shares in the last quarter. Nisa Investment Advisors LLC grew its position in shares of Protagonist Therapeutics by 10.4% during the fourth quarter. Nisa Investment Advisors LLC now owns 3,133 shares of the company's stock worth $121,000 after buying an additional 295 shares in the last quarter. Louisiana State Employees Retirement System increased its stake in shares of Protagonist Therapeutics by 1.1% in the fourth quarter. Louisiana State Employees Retirement System now owns 28,800 shares of the company's stock worth $1,112,000 after buying an additional 300 shares during the last quarter. KBC Group NV raised its holdings in Protagonist Therapeutics by 54.4% in the fourth quarter. KBC Group NV now owns 2,093 shares of the company's stock valued at $81,000 after acquiring an additional 737 shares in the last quarter. Finally, WINTON GROUP Ltd boosted its stake in Protagonist Therapeutics by 3.0% during the 4th quarter. WINTON GROUP Ltd now owns 26,768 shares of the company's stock valued at $1,033,000 after acquiring an additional 785 shares during the last quarter. 98.63% of the stock is owned by hedge funds and other institutional investors.

Remove Ads

Insider Buying and Selling

In other Protagonist Therapeutics news, insider Arturo Md Molina sold 30,514 shares of the company's stock in a transaction dated Thursday, March 13th. The shares were sold at an average price of $55.74, for a total transaction of $1,700,850.36. Following the completion of the sale, the insider now directly owns 83,892 shares of the company's stock, valued at approximately $4,676,140.08. This represents a 26.67 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, CEO Dinesh V. Ph D. Patel sold 5,359 shares of the firm's stock in a transaction dated Wednesday, February 19th. The stock was sold at an average price of $38.18, for a total transaction of $204,606.62. Following the completion of the transaction, the chief executive officer now owns 540,260 shares of the company's stock, valued at approximately $20,627,126.80. The trade was a 0.98 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 64,776 shares of company stock worth $3,585,010. Corporate insiders own 5.40% of the company's stock.

Protagonist Therapeutics Stock Performance

Shares of NASDAQ:PTGX traded up $2.51 on Tuesday, hitting $47.54. The company's stock had a trading volume of 440,981 shares, compared to its average volume of 831,516. The company has a market capitalization of $2.92 billion, a price-to-earnings ratio of 17.92 and a beta of 2.30. Protagonist Therapeutics, Inc. has a 12 month low of $24.22 and a 12 month high of $60.60. The stock's 50-day moving average is $44.19 and its two-hundred day moving average is $42.74.

Protagonist Therapeutics (NASDAQ:PTGX - Get Free Report) last issued its quarterly earnings results on Friday, February 21st. The company reported $1.98 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.09) by $2.07. The firm had revenue of $170.64 million during the quarter, compared to analyst estimates of $56.65 million. Protagonist Therapeutics had a return on equity of 34.68% and a net margin of 52.76%. Equities analysts expect that Protagonist Therapeutics, Inc. will post 2.43 earnings per share for the current fiscal year.

Analyst Ratings Changes

Several research firms have recently weighed in on PTGX. BMO Capital Markets boosted their target price on shares of Protagonist Therapeutics from $62.00 to $72.00 and gave the stock an "outperform" rating in a research report on Tuesday, March 11th. Wedbush reiterated an "outperform" rating and issued a $70.00 target price on shares of Protagonist Therapeutics in a research report on Friday, March 28th. The Goldman Sachs Group dropped their price target on Protagonist Therapeutics from $43.00 to $38.00 and set a "neutral" rating on the stock in a research report on Monday, February 24th. Truist Financial lifted their price objective on shares of Protagonist Therapeutics from $60.00 to $76.00 and gave the stock a "buy" rating in a report on Tuesday, March 11th. Finally, JPMorgan Chase & Co. increased their target price on shares of Protagonist Therapeutics from $53.00 to $57.00 and gave the stock an "overweight" rating in a report on Tuesday, March 4th. Two analysts have rated the stock with a hold rating, seven have given a buy rating and one has issued a strong buy rating to the company. According to MarketBeat.com, the company presently has an average rating of "Moderate Buy" and an average price target of $65.44.

About Protagonist Therapeutics

Protagonist Therapeutics, Inc, a biopharmaceutical company, develops peptide-based drugs for hematology and blood disorders, and inflammatory and immunomodulatory diseases. It is developing Rusfertide (PTG-300), an injectable hepcidin mimetic that completed phase 2 clinical trials for the treatment of polycythemia vera and other blood disorders; and JNJ-2113, an orally delivered investigational drug to block biological pathways that completed phase 2b clinical trials for the treatment of moderate-to-severe plaque psoriasis; and PN-943, an orally delivered, gut-restricted alpha 4 beta 7 specific integrin antagonist completed a phase 2 clinical trials in patients with moderate to severe ulcerative colitis.